RecruitingNCT05819528
Primary Cardiac Lymphoma: Italian Multicenter Experience
Sponsor
Fondazione Italiana Linfomi - ETS
Enrollment
43 participants
Start Date
Oct 2, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The rationale of this study is to provide an overview on PCL (Primary Cardiac Lymphoma) in Italy, trying to shed light on unknown aspects of the disease and on unanswered questions about its management that could be helpful in clinical practice.
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- Diagnosis of PCL (any histotype) defined as an extranodal lymphoma involving only the heart with possible involvement of the pericardium.
- Age ≥18 years.
- Diagnosis histologically confirmed. Cytofluorimetry analysis of pericardial fluid showing phenotypic features consistent with a primary cardiac lymphoma is permitted if a biopsy sample is not feasible/available for diagnosis; monoclonality is not accepted as a surrogate for diagnosis.
- Date of diagnosis: from 1st January 2000 to 31st December 2020.
- Only patients treated in first-line with chemoimmunotherapy regimens including an anti-CD20 monoclonal antibody are eligible for the study.
- Signed written informed consent (in case of unreachable subject please see chapter 11.2)
Exclusion Criteria3
- Secondary cardiac involvement from lymphoma; primary mediastinal lymphoma with pericardial infiltration or other lymphomas with involvement of the pericardium/the heart by contiguity and primary effusion lymphoma are not included in this study.
- Patients treated with chemotherapy regimens that did not include an anti-CD20 monoclonal antibody as first-line therapy.
- Refuse to sign a written informed consent
Locations(17)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05819528